![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Medical Solutn | LSE:MLS | London | Ordinary Share | GB0009739649 | ORD 2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 7.72 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Medical Solutions PLC 04 February 2008 For further information, please contact: Medical Solutions plc Nick Ash Managing Director Tel: 0115 973 9010 www.medical-solutions.co.uk Bishopsgate Communications Ltd Nick Rome/Gemma O'Hara Tel: 0207 562 3350 www.bishopsgatecommunications.com 4 February 2008 Medical Solutions plc ("Medical Solutions" or the "Company") Medical Solutions becomes first UK commercial service provider of Illumina next generation DNA sequencing and genotyping applications The Board of Medical Solutions plc (LSE: MLS), a UK-based provider of expert, quality DNA sequencing and genotyping services to the healthcare, pharma biotech and life sciences research sectors, is pleased to announce that it is implementing a new technology platform at its Nottingham laboratory that will help to broaden the Company's offering and increase efficiencies. Medical Solutions will become the UK's first commercial service provider for these leading edge systems, which it will be sourcing from Illumina, Inc. HIGHLIGHTS * Medical Solutions to offer both Illumina's Genome Analyzer, a next generation DNA sequencing system and Infinium whole genome genotyping on the BeadStation platform; * First commercial service provider of Illumina applications in the UK; * Complete pipeline of histopathology to genomic services, including DNA extraction, biobanking, whole genome amplification and DNA sequencing in GLP, GCP and CPA accredited laboratories Adoption of Illumina's DNA sequencing and genotyping platforms will complement Medical Solutions' extensive portfolio of diagnostic and contract research services ranging from cell and tissue to genomic analysis. This further demonstrates the Company's commitment to be a market leader in the UK for the provision of expert, quality laboratory services to the healthcare, pharma biotech and life science research sectors. Dr Tom Weaver, Commercial Director for Medical Solutions said, "We selected the Illumina platforms because the data quality, reproducibility, flexibility and breadth of applications are, in our opinion, the best in the industry. This represents cutting edge technology capable of revealing an enormous volume of genetic information. Customers have already expressed significant interest in applications run on the Genome Analyzer and BeadStation platforms, and it is our intention to develop strategic partnerships with these early adopters, enabling them to take full advantage of the power of whole genome analysis by providing high-quality data in an accredited quality laboratory environment. " Dr. Weaver added, "Illumina DNA sequencing and genotyping platforms are also capable of delivering analyses in the expanding field of personalised genomic services." "The addition of Illumina's Genome Analyzer and BeadStation platforms demonstrates the level of commitment Medical Solutions has to its customers and to providing them with leading-edge technologies that enable whole genome analysis" said Karen Possemato, Director of Corporate Marketing at Illumina. "Their added interest in becoming an Illumina CSPro further supports the value Medical Solutions sees in Illumina's products and how this program can be a key factor in their success." - ends - Notes to Editors: About Medical Solutions Medical Solutions is a leading provider of expert, quality services and products to the healthcare, pharma biotech and life science research sectors. Its Healthcare operations provide screening products and reference laboratory diagnostic testing services for cancer and other diseases and additional predictive testing for treatment optimisation for clinicians and patients. Pharma Biotech Services offers support for early stage therapeutic development, offering a "one-stop shop" from tissue pathology, immunohistochemistry, sophisticated image analysis, biomarker determination and assay development to pharmacogenomics including genotyping and gene expression analysis. The Life Science Research services provide core laboratory research support from conceptualization to implementation, calling upon a wide ranging of cutting-edge technology platforms including and an online catalogue of biomolecular tools. This incorporates DNA sequencing, whole genome amplification and a comprehensive library of genomic reagents and clones including cDNA and RNAi. The group has its headquarters in Nottingham, UK where it operates state of the art reference laboratory facilities, with additional UK laboratory facilities in Cambridge and Oxford. Medical Solutions is CPA, GLP and GCP accredited and is licensed by the Human Tissue Authority. About Illumina Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of next-generation life-science tools and integrated systems for the analysis of genetic variation and biological function. Using our proprietary technologies, we provide a comprehensive line of products and services that currently serve the sequencing, genotyping, and gene expression markets, and we expect to enter the market for molecular diagnostics. Our customers include leading genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, and biotechnology companies. Our tools provide researchers around the world with the performance, throughput, cost effectiveness, and flexibility necessary to perform the billions of genetic tests needed to extract valuable medical information from advances in genomics and proteomics. We believe this information will enable researchers to correlate genetic variation and biological function, which will enhance drug discovery and clinical research, allow diseases to be detected earlier, and permit better choices of drugs for individual patients. This information is provided by RNS The company news service from the London Stock Exchange END NRASSFFMFSASEDE
1 Year Medical Solutions Chart |
1 Month Medical Solutions Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions